Jenkem Technology Co (688356) Fair Value & Analysis
Basic Materials · CN · Market cap 4.2B CNY
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 29 days ago
Share price −0.2% over the past month.
A solid business, but screening 76% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥22.21). The favourable scenario is already priced in.
- Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥45.02 – ¥381.87 · fair‑value band ¥13.33 – ¥22.21 · the ¥74.50 price screens above the ¥17.77 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Jenkem Technology Co (688356) currently trades at ¥74.50, while our model-based Fair Value estimate is ¥17.77, implying the stock looks roughly 76.2% overvalued today. The Quality Score stands at 68/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Jenkem Technology Co generated revenue of 328M CNY at a net margin of 22.0%. Revenue grew 14.5% year over year. It earns a return on equity of 5.5%. The balance sheet holds a net cash position of 137M CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥13.33 (bear case) to ¥22.21 (bull case); at ¥74.50, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at -76%, 688356 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥27.12) versus Dividend Discount (¥2.27). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jenkem Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medical and pharmaceutical polyethylene glycol derivative (PEG) products in China and internationally.
Full company description
Jenkem Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medical and pharmaceutical polyethylene glycol derivative (PEG) products in China and internationally. The company offers high molecular weight polyethylene glycol derivatives comprising branched, methoxylated, bifunctionalized, heterofunctionalized disubstituted, multi-arm, multi-arm heterofunctional disubstituted, amino-polyglycolic, N-terminated polyethylene glycol-modified, and thiol-modified polyethylene glycol PEG products; monodisperse PEG products consisting of methoxy monodisperse PEG derivatives, and monodisperse PEG derivatives with the same functional and heterofunctional groups; click chemistry; lipid nanoparticles delivery system accessories; PEG linkers, such as ADC and PROTAC linkers; PEG medical devices, which include multi-arm PEG derivatives; polyethylene glycol standards; block copolymers; PEG standards; long-acting polypeptide fatty acid side chains, including semaglutide, tirzepatide/icodec, and somapacitan intermediates; and Silkrose injectable cross-linked sodium hyaluronate gel, a passive implantable device used to correct moderate to severe nasolabial folds through subcutaneous injection. It also provides technical services comprising development of synthetic methods, quality research and IND application, analytical method development, and polyethylene glycolization technology services. Jenkem Technology Co., Ltd. was incorporated in 2001 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jenkem Technology Co reported revenue of ¥316M in FY2025 versus ¥351M in FY2021, a compound −2.6%/yr. Reported net income was ¥63.4M in FY2025, compounding −22.5%/yr from FY2021.
688356 screens 76% overvalued. Compare with Linde plc →
Peer Group
Specialty Chemicals · 676 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $489.98 | $222.03 | -55% |
| Nan Ya Plastics Corporation 1303 | 181.50 TWD | 255.83 TWD | +41% |
| Wanhua Chemical Group 600309 | ¥70.04 | ¥68.03 | -3% |
| Novozymes A/S NSISB | kr 428.20 | kr 179.66 | -58% |
| Asian Paints Limited ASIANPAINT | ₹2,689 | ₹668.81 | -75% |
| Solar Industries India Limited SOLARINDS | ₹18,236 | ₹2,793 | -85% |
| Pidilite Industries Limited PIDILITIND | ₹1,560 | ₹351.84 | -77% |
| PT Chandra Asri Pacific Tbk TPIA | 1,805 IDR | 2,888 IDR | +60% |
| Linde India Limited LINDEINDIA | ₹7,115 | ₹757.93 | -89% |
| Berger Paints India Limited BERGEPAINT | ₹493.70 | ₹164.29 | -67% |
Compare Jenkem Technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Jenkem Technology Co (688356) overvalued or undervalued?
What is the fair value of 688356?
What is the quality score of 688356?
What is the revenue of Jenkem Technology Co (688356)?
What is the net profit margin of 688356?
Does Jenkem Technology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jenkem Technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.